Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXY)
OTHER OTC:RNLXY
RNLXY Stock Chart & Stats
$0.17
>-$0.01(-3.29%)
At close: 4:00 PM EST
$0.17
>-$0.01(-3.29%)
Day’s Range― - ―
52-Week Range$0.13 - $0.32
Previous CloseN/A
Volume36.17K
Average Volume (3M)33.15K
Market Cap
$39.11M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding218,509,340
10 Day Avg. Volume27,104
30 Day Avg. Volume33,149
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Renalytix News
RNLXY FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $0.13 and its highest was $0.32 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $39.11M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Mar 26, 2026 which is in 112 days.
How were Renalytix’s earnings last quarter?
Currently, no data Available
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 218,509,340 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in RNLXY
Company Description
Renalytix
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Technical Analysis
Rockwell Med
―
Rein Therapeutics
―
Lantern Pharma
―
Generation Bio
―
Connect Biopharma Holdings
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---